VANCOUVER and MINNEAPOLIS, April 28, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire-- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced progress towards its value creation ...

VANCOUVER, - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development ...

“We are encouraged by the growing use and satisfaction of physicians with the outcomes of the Reducer Therapy for their patients,” said Fred Colen, President and Chief Executive Officer of Neovasc.

Participating Hospitals in Germany Now Eligible to Negotiate Reimbursement for Reducer Procedure VANCOUVER, Jan. 31, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the ...

VANCOUVER and MINNEAPOLIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire-- Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced that the Centers for Medicare and Medicaid ...

Tiara™ Transcatheter Mitral Valve program featured in multiple scientific presentations Washington DC – Neovasc Inc. (“Neovasc” or the “Company”) announced today that its Reducer™ technology was ...

Vancouver, Bristish Columbia and Minneapolis, Minnesota--(Newsfile Corp. - January 19, 2021) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company ...

Neovasc Inc. shares soared more than 24% in premarket trade Wednesday, after the company announced positive data from the first U.S. patient to be implanted with a device to treat refractory angina.

Shockwave Medical Inc. will acquire Neovasc Inc. for just under $108 million, if all terms of the deal are met. Shockwave will pay $27.25 in cash for each of Neovasc’s 2.71 million outstanding shares ...